Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Natural History of Non-Infectious, Ibrutinib-Attributable Adverse Events Leading to Alternative BTK Inhibitor Use in CLL

Polina Shindiapina, MD PhD, Soun Khountham, Kerry A. Rogers, MD, Jeffrey Jones, MD MPH, Leslie Andritsos, MD, Kami J. Maddocks, MD, Joseph M. Flynn, DO, MPH, Jennifer A. Woyach, MD, John C. Byrd, MD, Farrukh T. Awan

Blood (2016) 128 (22): 4385.

https://doi.org/10.1182/blood.V128.22.4385.4385

Published: 2016

Journal Articles

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Blood (2016) 128 (22): 55.

https://doi.org/10.1182/blood.V128.22.55.55

Published: 2016

Journal Articles

Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib

Blood (2016) 128 (22): 3198.

https://doi.org/10.1182/blood.V128.22.3198.3198

Published: 2016

Journal Articles

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

John C. Byrd, Joseph M. Flynn, Thomas J. Kipps, Michael Boxer, Kathryn S. Kolibaba, David J. Carlile, Guenter Fingerle-Rowson, Nicola Tyson, Jamie Hirata, Jeff P. Sharman

Blood (2016) 127 (1): 79–86.

https://doi.org/10.1182/blood-2015-03-634394

Published: 2016

Journal Articles

A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and I n Vi tro Potency in B-Cell Malignancies

Dalia El-Gamal, PhD, Zachary A. Hing, BS, Shaneice Mitchell, BS, Taylor D. LaFollette, Paul J. Brennan, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD MPH, Farrukh Awan, MD MS, Leslie A. Andritsos, MD, James S. Blachly, MD, Katie Williams, MS, Bonnie K. Harrington, DVM, Virginia M. Goettl, DVM, PhD, Jennifer A. Woyach, MD, Amy M. Lehman, MAS, Lianbo Yu, PhD, John C. Byrd, MD, Rosa Lapalombella, PhD

Blood (2015) 126 (23): 318.

https://doi.org/10.1182/blood.V126.23.318.318

Published: 2015

Journal Articles

A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Galena Salem, MD, Deborah M. Stephens, DO, Leslie A. Andritsos, MD, Farrukh T. Awan, MD MS, John C. Byrd, MD, Joseph M. Flynn, DO, MPH, Kami J. Maddocks, MD, Ying Huang, MA, MS, Amy S. Ruppert, MAS, Jeffrey A. Jones, MD MPH

Blood (2015) 126 (23): 2951.

https://doi.org/10.1182/blood.V126.23.2951.2951

Published: 2015

Journal Articles

Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study

Blood (2015) 126 (7): 842–850.

https://doi.org/10.1182/blood-2014-12-617522

Published: 2015

Includes: Supplemental data

Journal Articles

The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL)

Blood (2014) 124 (21): 396.

https://doi.org/10.1182/blood.V124.21.396.396

Published: 2014

Journal Articles

Incidence of Autoimmune Cytopenias (AIC) in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Patients (pts) Treated with Ibrutinib

Kerry A. Rogers, MD, Jennifer A. Woyach, MD, Leslie A. Andritsos, MD, Farrukh Awan, MD MS, Kristie A. Blum, MD, Joseph M Flynn, DO, MPH, Samantha Jaglowski, MD MPH, Gerard Lozanski, MD, Kami J. Maddocks, MD, John C. Byrd, MD, Jeffrey A. Jones, MD

Blood (2014) 124 (21): 1997.

https://doi.org/10.1182/blood.V124.21.1997.1997

Published: 2014

Journal Articles

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia

Deborah M Stephens, DO, Kyle A Beckwith, B.S., Carolyn Cheney, B.S, Xiaokui Mo, PhD MAS, Joseph M Flynn, D.O., MPH, Jeffrey A. Jones, MD, Kami J. Maddocks, MD, Karl-Heinz Heider, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2014) 124 (21): 4681.

https://doi.org/10.1182/blood.V124.21.4681.4681

Published: 2014

Journal Articles

A Phase II Study of MLN8237 (Alisertib) Alone and in Combination with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (NHL)

Kami J. Maddocks, MD, Jonathon B. Cohen, MD, Beth Christian, MD, Joseph M Flynn, DO, MPH, Samantha M. Jaglowski, MD MPH, Kristie A. Blum, MD

Blood (2014) 124 (21): 3082.

https://doi.org/10.1182/blood.V124.21.3082.3082

Published: 2014

Journal Articles

Poor Overall Survival of Patients with Ibrutinib-Resistant Mantle Cell Lymphoma

Peter Martin, MD, Kami J. Maddocks, MD, Katherine Noto, Beth Christian, MD, Richard R. Furman, MD, Leslie A. Andritsos, MD, Joseph M Flynn, D.O., MPH, Jeffrey A. Jones, MD, Jia Ruan, MD PhD, Selina Chen-Kiang, PhD, Maurizio Di Liberto, PhD, John P. Leonard, MD, Kristie A. Blum, MD

Blood (2014) 124 (21): 3047.

https://doi.org/10.1182/blood.V124.21.3047.3047

Published: 2014

Journal Articles

Dinaciclib (SCH 727965) and Ofatumumab for the Treatment of Relapsed and Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Results of a Phase 1b/2 Study

Jeffrey Alan Jones, MD MPH, Susan Geyer, PhD, Leslie A. Andritsos, MD, Farrukh Awan, MD MS, Joseph M Flynn, DO, MPH, Kami J. Maddocks, MD, Anissa Bingman, M.S., Amy J. Johnson, PhD, Nyla A. Heerema, PhD, Cathy Brookfield, RN, John C. Byrd, MD, Michael R. Grever, MD

Blood (2014) 124 (21): 329.

https://doi.org/10.1182/blood.V124.21.329.329

Published: 2014

Journal Articles

Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing

Jason A. Dubovsky, Danielle L. Chappell, Bonnie K. Harrington, Kitty Agrawal, Leslie A. Andritsos, Joseph M. Flynn, Jeffrey A. Jones, Michael E. Paulaitis, Brad Bolon, Amy J. Johnson, John C. Byrd, Natarajan Muthusamy

Blood (2013) 122 (19): 3308–3316.

https://doi.org/10.1182/blood-2013-05-504597

Published: 2013

Includes: Supplemental data

Journal Articles

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Blood (2013) 122 (15): 2539–2549.

https://doi.org/10.1182/blood-2013-06-507947

Published: 2013

Includes: Supplemental data

Journal Articles

Identification of Endoplasmic Reticulum Stress Inducing Agents by Antagonizing Autophagy: A New Potential Strategy for Identification of Anti-Cancer Therapeutics in B-Cell Malignancies.

Emilia Mahoney, MD, PhD, Sara L Cole, PhD, Kami Maddocks, MD, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, Xiaoli Zhang, PhD, MS, John C. Byrd, MD, Amy J. Johnson, PhD

Blood (2012) 120 (21): 2473.

https://doi.org/10.1182/blood.V120.21.2473.2473

Published: 2012

Journal Articles

Complex Karyotype (CK) Is Associated with a Shortened Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL).

Jonathon B. Cohen, MD, Amy S. Ruppert, MAS, Nyla A. Heerema, PhD, Jeffrey A. Jones, MD, MPH, Pierluigi Porcu, MD, Robert A. Baiocchi, M.D., Ph.D., Beth Christian, MD, John C. Byrd, MD, Joseph M. Flynn, DO, MPH, Sam Penza, MD, Leslie A Andritsos, MD, Steven M. Devine, MD, Kristie A. Blum, MD

Blood (2012) 120 (21): 2691.

https://doi.org/10.1182/blood.V120.21.2691.2691

Published: 2012

Journal Articles

Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma.

Craig C. Hofmeister, MD, Zhongfa Liu, Ph.D., Mindy A Bowers, BS, Pierluigi Porcu, MD, Joseph M. Flynn, DO, MPH, Beth Christian, MD, Robert A. Baiocchi, M.D., Ph.D., Don M. Benson, Jr., MD, PhD, Leslie A Andritsos, MD, Carli N Greenfield, RN, MSN, ACNP, Megan Sell, RN, MS, Susan Geyer, PhD, John C. Byrd, MD, Michael R. Grever, MD

Blood (2012) 120 (21): 2955.

https://doi.org/10.1182/blood.V120.21.2955.2955

Published: 2012

Journal Articles

A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)

Kristie A. Blum, MD, Beth Christian, MD, Joseph M. Flynn, DO, MPH, Samantha M. Jaglowski, MD, MPH, Jeffrey Alan Jones, MD, MPH, Kami Maddocks, MD, John C. Byrd, MD

Blood (2012) 120 (21): 1643.

https://doi.org/10.1182/blood.V120.21.1643.1643

Published: 2012

Journal Articles

Fatigue, Distress, and Quality of Life As Covariates for Early-Stage Chronic Lymphocytic Leukemia

Eleshia Morrison, M.A., Joseph M Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, John C. Byrd, MD, Barbara L Andersen, PhD

Blood (2012) 120 (21): 2075.

https://doi.org/10.1182/blood.V120.21.2075.2075

Published: 2012

NARROW

Natural History of Non-Infectious, Ibrutinib-Attributable Adverse Events Leading to Alternative BTK Inhibitor Use in CLL

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and I n Vi tro Potency in B-Cell Malignancies

A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia

Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study

The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL)

Incidence of Autoimmune Cytopenias (AIC) in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Patients (pts) Treated with Ibrutinib

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia

A Phase II Study of MLN8237 (Alisertib) Alone and in Combination with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (NHL)

Poor Overall Survival of Patients with Ibrutinib-Resistant Mantle Cell Lymphoma

Dinaciclib (SCH 727965) and Ofatumumab for the Treatment of Relapsed and Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Results of a Phase 1b/2 Study

Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Identification of Endoplasmic Reticulum Stress Inducing Agents by Antagonizing Autophagy: A New Potential Strategy for Identification of Anti-Cancer Therapeutics in B-Cell Malignancies.

Complex Karyotype (CK) Is Associated with a Shortened Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL).

Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma.

A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)

Fatigue, Distress, and Quality of Life As Covariates for Early-Stage Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only